COPD Flashcards
1
Q
Short-acting Beta Agonist
Common indications
A
- COPD- releive breathlessness brought on by exercise
- Asthma- used in conjunction with other agents
- Hyperkalaemia- nebulised salbutamol may be used in conjunction with other treatments for the urgent treatment of hyperkalaemia
2
Q
B2-agonist MOA
A
- B2-receptors are found on the smooth muscle of the bronchi, GIT, uterus and blood vessels
- Stimulation of the GPCR activates a signalling cascade that leads to the relaxation of smooth muscle
- Improves airflow reduce SOB
- B2-agonist stimulates Na/K/ATPase pumps on the cell surface
- Shifting K into the cell- useful for hyperkalaemia
3
Q
B2-Agonist important side effects
A
- Tachycardia
- Palpitations
- Anxiety
- Tremor
- Increase serum glucose levels- diabetes
- Muscle cramps
4
Q
B2-agonist
Warnings
A
- Only use LABA in asthma if there is an ICS treatment used as well
- Without the steroid there is an increase mortality rate
- Care should be given to people with CVD
- Tachycardia= worsen angina, provoke arrhythmias
- Especially important when using as part of the hyperkalaemia treatment
5
Q
B2-agonist important interactions
A
- Beta blockers- may reduce the effectiveness of the agonist
- Extensive use of B2 with ICS and theophylline may lead to hypokalaemia monitor U&E
6
Q
B2- agonist
Monitoring + advise
A
- Symptom severity
- Peak flow meter
- Spirometry
- Exacerbations
- Tell patients this will help there breathing (symptoms) but not treat/cure the disease.
- If they need to use B2-agonist regularly then they need to get there other inhalers stepped up
- Make sure they clean their inhaler regularly
7
Q
ICS
Common indications
A
- Asthma- treat airway inflammation and control symptoms at step 2 of asthma therapy when SABA fails
- COPD- to control symptoms and prevent exacerbations in patients who have severe airflow obstruction on spirometry and or recurrent exacerbations
- Can be used in combination with LABA + LAMA
8
Q
ICS
Mechanism of action
A
- Corticosteroids pass through the plasma membrane and interact with receptors in the cytoplasm
- The activated receptor then passes into the nucleus to modify transcription of a large number of genes
- Pro-inflammatory cytokines, interleukins and chemokines are downregulated
- While anti-inflammatory proteins are upregulated
- In the airways this reduces mucosal inflammation, widens the airways and reduces mucus secretion
- Improves symptoms
9
Q
ICS
Important adverse events
A
- Immunosupressive effect in the mouth increases risk of oral thrush
- Hoarse voice
- In COPD, they can increase the risk of pneumonia
- Very little is absorbed into the blood, so there are few systematic adverse effect unless very high doses are used
10
Q
ICS
Warnings
A
- High doses- use in caution in COPD patients with a history of pneumonia
- Children- growth suppression
11
Q
Antimuscarinic bronchodilators
Common indications
A
- Asthma
- COPD
12
Q
Antimuscarinic bronchodilators
MOA
A
- Antimuscarinic drugs bind to the muscarinic receptors, where they act as a competitive inhibitor of acetylcholine
- Stimulation of the muscarinic receptors brings about a wide range of parasympathetic rest and digest effects
- In blocking the receptor, antimuscarinic have the opposite effect
- Reduce smooth muscle tone
- Reduce secretion from glands in the respiratory and GIT
- Relaxation of pupillary constrictor, ciliary muscles preventing accommodation in the eye
13
Q
Antimuscarinic bronchodilators
Adverse effects
A
- When antimuscarinic bronchodilators are taken by inhalation, there is relatively little systematic absorption
- Adverse effects, apart from dry mouth are uncommon
14
Q
Antimuscarinic bronchodilators
Warnings
A
- Antimuscarinics should be used with caution in patients susceptible to angle-closure glaucoma, in whom they can precipitate a dangerous rise in intraocular pressure
- They should be used with caution in patients with or at risk of arrhythmias
- However, in practice, most patients can take these drugs by inhalation without major problems
15
Q
Antimuscarinic bronchodilators
A